How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

713 results for

Long-acting Anticholinergic Bronchodilator

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long-acting Anticholinergic Bronchodilator

Long-acting Anticholinergic Bronchodilator Long-acting Anticholinergic Bronchodilator Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Long-acting Anticholinergic Bronchodilator Long-acting Anticholinergic Bronchodilator Aka: Long-acting Anticholinergic Bronchodilator , Long-Acting Muscarinic Antagonist , Tiotropium , Spiriva , Aclidinium , Tudorza , Umeclidinium , Incruse , Anoro Ellipta , Seebri Neohaler , Inhaled Glycopyrolate , Stiolto , Utibron , Lonhala Magnair From Related Chapters II. Indication ( ) (third-line agent) May be added to high dose and long acting beta agonist However, other standard agents are preferred first

2018 FP Notebook

2. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in patients with COPD.We identified a cohort of COPD patients, new users of LABA or the LAMA tiotropium during 2002-2012, from the UK Clinical Practice (...) Research Datalink. Using high-dimensional propensity scores, each patient adding a second bronchodilator was matched with a patient who remained on monotherapy. Patients were followed for 1 year for the occurrence of acute myocardial infarction (AMI), stroke, heart failure and arrhythmia.The cohorts included up to 31 174 patients adding a bronchodilator matched to 31 174 patients remaining on bronchodilator monotherapy. Adding a long-acting bronchodilator, compared to remaining on monotherapy

2017 EvidenceUpdates

3. Short-acting Anticholinergic Bronchodilator

Short-acting Anticholinergic Bronchodilator Short-acting Anticholinergic Bronchodilator Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration (...) 4 Short-acting Anticholinergic Bronchodilator Short-acting Anticholinergic Bronchodilator Aka: Short-acting Anticholinergic Bronchodilator , Ipratropium , Ipratropium Bromide , Atrovent , Combivent , Combivent Respimat From Related Chapters II. Indications ( ) III. Mechanism Short-acting Anticholinergic Bronchodilator IV. Preparations: Ipratropium Bromide Atrovent MDI: 2-3 puffs three to four times daily Atrovent Nebulization: 1 ampule in nebulization solution every 6 hours prn V. Preparations

2018 FP Notebook

4. The future of the long-acting beta-adrenergic bronchodilators in the treatment of asthma. (PubMed)

The future of the long-acting beta-adrenergic bronchodilators in the treatment of asthma. The combination of long-acting beta-agonist (LABA) bronchodilators with inhaled corticosteroids (ICSs) has been shown to be an extremely effective treatment for asthma. Use of LABA as monotherapy for asthma is associated with increased adverse events including exacerbations and asthma deaths. However, intensive evaluation of the combined LABA-ICS therapy provided no signals of increased risk. LABA appears (...) adherence and improve asthma outcomes. The 24-hour LABA will likely be combined with a 24-hour anticholinergic to treat chronic obstructive pulmonary disease. Whether this dual combination with ICS will enhance our treatment of more severe asthma remains an exciting hypothesis to be tested.

2017 Allergy and Asthma Proceedings

5. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. (PubMed)

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in patients with COPD.We identified a cohort of COPD patients, new users of LABA or the LAMA tiotropium during 2002-2012, from the UK Clinical Practice (...) Research Datalink. Using high-dimensional propensity scores, each patient adding a second bronchodilator was matched with a patient who remained on monotherapy. Patients were followed for 1 year for the occurrence of acute myocardial infarction (AMI), stroke, heart failure and arrhythmia.The cohorts included up to 31 174 patients adding a bronchodilator matched to 31 174 patients remaining on bronchodilator monotherapy. Adding a long-acting bronchodilator, compared to remaining on monotherapy

2017 European Respiratory Journal

6. Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD. (PubMed)

Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD. This randomized, double-blind, crossover study examined the physiological rationale for using a dual long-acting bronchodilator (umeclidinium/vilanterol (UME/VIL)) versus its muscarinic-antagonist component (UME) as treatment for dyspnea and exercise intolerance in moderate COPD. After each 4-week treatment period, subjects performed pulmonary function and symptom-limited constant-work rate cycling

2018 Respiratory physiology & neurobiology Controlled trial quality: uncertain

7. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? (PubMed)

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? Despite current guidelines and the range of available treatments, over a half of patients with asthma continue to suffer from poor symptomatic control and remain at risk of future worsening. Although a number of non-pharmacological measures are crucial for good clinical management of asthma, new therapeutic controller medications will have a role in the future management of the disease. Several long-acting (...) anticholinergic bronchodilators are under investigation or are available for the treatment of respiratory diseases, including tiotropium bromide, aclidinium bromide, glycopyrronium bromide, glycopyrrolate and umeclidinium bromide, although none is yet licensed for the treatment of asthma. A recent Phase III investigation demonstrated that the once-daily long-acting anticholinergic bronchodilator tiotropium bromide improves lung function and reduces the risk of exacerbation in patients with symptomatic asthma

Full Text available with Trip Pro

2014 NPJ primary care respiratory medicine

8. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. (PubMed)

Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. There are several treatment options for managing acute asthma exacerbations (sustained worsening of symptoms that do not subside with regular treatment and require a change in management). Guidelines advocate the use of inhaled short acting beta2-agonists (SABAs) in children experiencing an asthma exacerbation. Anticholinergic agents, such as ipratropium bromide and atropine (...) sulfate, have a slower onset of action and weaker bronchodilating effect, but may specifically relieve cholinergic bronchomotor tone and decrease mucosal edema and secretions. Therefore, the combination of inhaled anticholinergics with SABAs may yield enhanced and prolonged bronchodilation.To determine whether the addition of inhaled anticholinergics to SABAs provides clinical improvement and affects the incidence of adverse effects in children with acute asthma exacerbations.We searched MEDLINE (1966

Full Text available with Trip Pro

2013 Cochrane

9. Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)

Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) (LAB-Card) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2016 Clinical Trials

10. Long-acting bronchodilator initiation in COPD and the risk of adverse cardio-pulmonary events: A population-based comparative safety study. (PubMed)

Long-acting bronchodilator initiation in COPD and the risk of adverse cardio-pulmonary events: A population-based comparative safety study. Long-acting bronchodilators, including long-acting beta2-agonists (LABA) and the anticholinergic tiotropium, are recommended as initial maintenance therapy in COPD. Studies to date have been limited in size and reported ambivalent results on the comparative risk of cardiovascular, cerebrovascular, and pulmonary adverse events between these two long-acting (...) bronchodilators. Moreover, little information is available for the period when treatment is first initiated, a time when subjects may be especially at risk.We identified a cohort of new users of long-acting bronchodilators between 2002 and 2012, age 55 or older, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating tiotropium were matched on high-dimensional propensity scores and prior inhaled corticosteroid use with patients initiating LABAs, and followed for 1 year

2016 Chest

11. Long-acting Anticholinergic Bronchodilator

Long-acting Anticholinergic Bronchodilator Long-acting Anticholinergic Bronchodilator Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Long-acting Anticholinergic Bronchodilator Long-acting Anticholinergic Bronchodilator Aka: Long-acting Anticholinergic Bronchodilator , Long-Acting Muscarinic Antagonist , Tiotropium , Spiriva , Aclidinium , Tudorza , Umeclidinium , Incruse , Anoro Ellipta , Seebri Neohaler , Inhaled Glycopyrolate , Stiolto , Utibron , Lonhala Magnair From Related Chapters II. Indication ( ) (third-line agent) May be added to high dose and long acting beta agonist However, other standard agents are preferred first

2015 FP Notebook

12. Long-Acting Beta2-Agonists for Chronic Obstructive Pulmonary Disease

years; 76% male; N = 255 No clinically relevant differences in QTc interval (Fridericia’s) between groups; cardiovascular safety profile similar to placebo Non-Randomized Studies Gershon, 2013; 13 Data from Ontario health care database covering 5.5 years • New use of LABAs • New use of long-acting anticholinergic Patients with COPD; age = 60 years; N = 191,005 No significant difference in cardiovascular events between the 2 types of medications Wilchesky, 2012; 14 Data from Saskatchewan health care (...) of LABAs slightly increased the risk of cardiac arrhythmia Pascoe, 2011; 16 Single dose • Indacaterol 400 mcg • Indacaterol 1,000 mcg • Indacaterol 2,000 mcg • Indacaterol 3,000 mcg Patients with mild to moderate COPD; ages 43-72 years; N = 16 No clinically significant ECG abnormalities occurred Worth, 2011; 17 Clinical trial database comprised of studies = 6 months duration • Indacaterol • Other long-acting bronchodilators (formoterol, salmeterol, tiotropium) • Placebo Patients with moderate to severe

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. (PubMed)

Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. International guidelines provide conflicting recommendations on how to use bronchodilators to manage childhood acute wheezing conditions in the emergency department (ED), and there is variation within and among countries in how these conditions are managed. This may be reflective of uncertainty about the evidence. This overview of systematic reviews (SRs) aimed to synthesize, appraise (...) , and present all SR evidence on the efficacy and safety of inhaled short-acting bronchodilators to treat asthma and wheeze exacerbations in children 0-18 years presenting to the ED. Searching, review selection, data extraction and analysis, and quality assessments were conducted using methods recommended by The Cochrane Collaboration. Thirteen SRs containing 56 relevant trials and 5526 patients were included. Results demonstrate the efficacy of short-acting beta-agonist (SABA) delivered by metered-dose

Full Text available with Trip Pro

2016 Allergy

14. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. (PubMed)

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Pharmacological therapy for chronic obstructive pulmonary disease (COPD) is aimed at relieving symptoms, improving quality of life and preventing or treating exacerbations.Treatment tends to begin with one inhaler, and additional therapies are introduced as necessary. For persistent or worsening symptoms, long-acting inhaled therapies taken once or twice daily are preferred over short (...) -acting inhalers. Several Cochrane reviews have looked at the risks and benefits of specific long-acting inhaled therapies compared with placebo or other treatments. However for patients and clinicians, it is important to understand the merits of these treatments relative to each other, and whether a particular class of inhaled therapies is more beneficial than the others.To assess the efficacy of treatment options for patients whose chronic obstructive pulmonary disease cannot be controlled by short

Full Text available with Trip Pro

2014 Cochrane database of systematic reviews (Online)

15. V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. (PubMed)

V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. Long acting bronchodilators are the standard of care in the management of chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the efficacy and safety of V0162, a novel anticholinergic agent with bronchodilator properties, in preclinical models and in patients with COPD.Guinea pigs were used to evaluate the impact of V0162 (...) the safety and efficacy of V0162, in terms of bronchodilation and reduction in hyperinflation.Preclinical results showed that V0162 was able to prevent bronchoconstriction induced either by acetylcholine or histamine. V0162 reversed the bronchoconstriction and airway inflammation caused by ovalbumin challenge in sensitized guinea pigs. In the healthy volunteers study, 88 subjects were enrolled: 66 received V0162 and 22 received placebo. No particular safety concerns were raised. The maximal tolerated

Full Text available with Trip Pro

2015 Respiratory research Controlled trial quality: uncertain

16. Short-acting anticholinergic bronchodilation does not increase cardiovascular events in smokers with mild to moderate pulmonary obstruction. (PubMed)

Short-acting anticholinergic bronchodilation does not increase cardiovascular events in smokers with mild to moderate pulmonary obstruction. We hypothesized that bronchodilation in patients with chronic obstructive pulmonary disease (COPD) increases the smoke-related risk to develop cardiovascular disease, and aimed to study the effect of short-acting anticholinergic bronchodilation and smoking on cardiovascular events.We performed a secondary analysis on data from the Lung Health Study (...) for a cardiovascular event, and 94 participants due to a coronary event. Survival analysis revealed no effect between smoking and short-acting anticholinergic bronchodilation on fatal and/or non-fatal cardiovascular events, hazard ratio = 1.12 (0.58-2.19), nor on coronary events, hazard ratio = 1.46 (0.60-3.56).Our study results show that short-acting anticholinergic bronchodilation had no detrimental effect on cardiovascular disease in smokers with mild to moderate pulmonary obstruction.© 2012 The Authors

2013 Respirology Controlled trial quality: uncertain

17. Short-acting anticholinergic bronchodilation does not increase cardiovascular events in smokers with mild to moderate pulmonary obstruction. (PubMed)

Short-acting anticholinergic bronchodilation does not increase cardiovascular events in smokers with mild to moderate pulmonary obstruction. We hypothesized that bronchodilation in patients with chronic obstructive pulmonary disease (COPD) increases the smoke-related risk to develop cardiovascular disease, and aimed to study the effect of short-acting anticholinergic bronchodilation and smoking on cardiovascular events.We performed a secondary analysis on data from the Lung Health Study (...) for a cardiovascular event, and 94 participants due to a coronary event. Survival analysis revealed no effect between smoking and short-acting anticholinergic bronchodilation on fatal and/or non-fatal cardiovascular events, hazard ratio = 1.12 (0.58-2.19), nor on coronary events, hazard ratio = 1.46 (0.60-3.56).Our study results show that short-acting anticholinergic bronchodilation had no detrimental effect on cardiovascular disease in smokers with mild to moderate pulmonary obstruction.© 2012 The Authors

2013 Respirology (Carlton, Vic.) Controlled trial quality: uncertain

18. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. (PubMed)

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Long-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropium are commonly used, either on their own or in combination, for managing persistent symptoms of chronic obstructive pulmonary disease. Patients with severe chronic obstructive pulmonary disease who are symptomatic and who suffer repeated exacerbations (...) are recommended to add inhaled corticosteroids to their bronchodilator treatment. However, the benefits and risks of adding inhaled corticosteroid to tiotropium and long-acting beta(2)-agonists for the treatment of chronic obstructive pulmonary disease are unclear.To assess the relative effects of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists treatment in patients with chronic obstructive pulmonary disease.We searched the Cochrane Airways Group Specialised Register of trials

Full Text available with Trip Pro

2011 Cochrane

19. Short-acting Anticholinergic Bronchodilator

Short-acting Anticholinergic Bronchodilator Short-acting Anticholinergic Bronchodilator Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration (...) 4 Short-acting Anticholinergic Bronchodilator Short-acting Anticholinergic Bronchodilator Aka: Short-acting Anticholinergic Bronchodilator , Ipratropium , Ipratropium Bromide , Atrovent , Combivent , Combivent Respimat From Related Chapters II. Indications ( ) III. Mechanism Short-acting Anticholinergic Bronchodilator IV. Preparations: Ipratropium Bromide Atrovent MDI: 2-3 puffs three to four times daily Atrovent Nebulization: 1 ampule in nebulization solution every 6 hours prn V. Preparations

2015 FP Notebook

20. Aclidinium in the management of COPD. Besides an anticholinergic agent, what else do we know about this drug?

of COPD (Bretaris Genuair®, Eklira Genuair®) Content tools Share it Besides an anticholinergic agent, what else do we know about this drug? There is no head-to-head trial comparing aclidinium vs other long-acting bronchodilators. Compared to placebo, aclidinium 400 mcg/12h improves spirometry parameters although the clinical relevance of this improvement is modest. Adverse effects related to heart conduction have been reported, and the EMA has requested a post-approval study to monitor cardiovascular (...) Aclidinium in the management of COPD. Besides an anticholinergic agent, what else do we know about this drug? 2014. DAR No 1. Aclidinium, as maintenance therapy in the management of COPD (Bretaris Genuair®, Eklira Genuair®) - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 1. Aclidinium, as maintenance therapy in the management of COPD (Bretaris Genuair®, Eklira Genuair®) DAR No 1. Aclidinium, as maintenance therapy in the management

2014 Drug and Therapeutics Bulletin of Navarre (Spain)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>